Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.
The androgen receptor (AR) is expressed in a subset of prostate stromal cells and functional stromal cell AR is required for normal prostate developmental and influences the growth of prostate tumors. Although we are broadly aware of the specifics of the genomic actions of AR in prostate cancer cells, relatively little is known regarding the gene targets of functional AR in prostate stromal cells. Here, we describe a novel human prostate stromal cell model that enabled us to study the effects of AR on gene expression in these cells. The model involves a genetically manipulated variant of immortalized human WPMY-1 prostate stromal cells that overexpresses wildtype AR (WPMY-AR) at a level comparable to LNCaP cells and is responsive to dihydrotestosterone (DHT) stimulation. Use of WPMY-AR cells for gene expression profiling showed that the presence of AR, even in the absence of DHT, significantly altered the gene expression pattern of the cells compared to control (WPMY-Vec) cells. Treatment of WPMY-AR cells, but not WPMY-Vec control cells, with DHT resulted in further changes that affected the expression of 141 genes by 2-fold or greater compared to vehicle treated WPMY-AR cells. Remarkably, DHT significantly downregulated more genes than were upregulated but many of these changes reversed the initial effects of AR overexpression alone on individual genes. The genes most highly effected by DHT treatment were categorized based upon their role in cancer pathways or in cell signaling pathways (transforming growth factor-β, Wnt, Hedgehog and MAP Kinase) thought to be involved in stromal-epithelial crosstalk during prostate or prostate cancer development. DHT treatment of WPMY-AR cells was also sufficient to alter their paracrine potential for prostate cancer cells as conditioned medium from DHT-treated WPMY-AR significantly increased growth of LNCaP cells compared to DHT-treated WPMY-Vec cell conditioned medium.
Ordway Research Institute, Albany, New York, United States of America.
Matthew J
MJ
Tanner
R Charles
RC
Welliver
Mengqian
M
Chen
Michael
M
Shtutman
Alejandro
A
Godoy
Gary
G
Smith
Badar M
BM
Mian
Ralph
R
Buttyan
D000728:Androgens / Q000494:pharmacology*; D045744:Cell Line, Tumor; D013196:Dihydrotestosterone / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D008297:Male; D019899:Paracrine Communication; D011467:Prostate / Q000166:cytology / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011944:Receptors, Androgen / Q000235:genetics*; D017154:Stromal Cells / Q000378:metabolism
D000728:Androgens; D011944:Receptors, Androgen; D013196:Dihydrotestosterone
Differentiation. 2002 Dec;70(9-10):473-85
12492490
J Urol. 2009 Aug;182(2):499-507; discussion 508
19524966
J Urol. 2010 Jul;184(1):344-51
20488474
Int J Cancer. 2003 Oct 20;107(1):1-10
12925950
Cancer Res. 2007 Jan 15;67(2):511-9
17234758
Prostate. 2004 Dec 1;61(4):332-53
15389811
Prostate. 1997 Feb 15;30(3):145-53
9122038
Clin Cancer Res. 1996 May;2(5):889-95
9816246
J Steroid Biochem Mol Biol. 1993 Nov;46(5):519-30
8240973
Mol Cell Endocrinol. 1997 Jan 3;126(1):59-73
9027364
J Urol. 2000 Dec;164(6):2145-50
11061945
Cancer Res. 2009 Sep 1;69(17):7111-20
19706777
Oncogene. 2009 May 14;28(19):2051-63
19363526
Genome Res. 2007 Oct;17(10):1537-45
17785539
Clin Cancer Res. 2009 Jan 1;15(1):39-47
19118031
Int J Cancer. 2001 May 1;92(3):322-8
11291065
J Cell Biochem. 2006 Oct 1;99(2):333-44
16518832
Prostate. 2009 Jun 15;69(9):949-55
19274665
Cancer Res. 2004 Oct 1;64(19):7156-68
15466214
Cancer Res. 1991 Jul 15;51(14):3753-61
1712249
Mol Cell Endocrinol. 2002 Dec 30;198(1-2):51-9
12573814
Oncogene. 2005 May 26;24(23):3847-52
15750627
Carcinogenesis. 1999 Jul;20(7):1185-92
10383888
Mol Endocrinol. 2009 Nov;23(11):1927-33
19762544
J Steroid Biochem Mol Biol. 2004 Nov;92(4):221-36
15663986
Endocrinology. 2004 Aug;145(8):3913-24
15131019
BMC Med Genomics. 2009 Aug 04;2:48
19653896
Oncogene. 2008 Nov 27;27(56):7118-30
18724388
Mol Cancer. 2007 Jun 06;6:39
17553165
Cell Cycle. 2009 Jan 1;8(1):149-57
19158486
J Histochem Cytochem. 1994 Jun;42(6):783-8
8189040
Cancer Inform. 2007 Feb 21;2:289-300
19458772
Int J Oncol. 2007 Jan;30(1):19-32
17143509
J Urol. 2005 Jan;173(1):10-20
15592017
Endocrinology. 1990 Dec;127(6):3180-6
1701137